NCT06500169 Golf Recreational Exercise for Enhanced Survivorship in Prostate Cancer Survivors
| NCT ID | NCT06500169 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Southern California |
| Condition | Localized Prostate Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2023-09-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2023-09-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial evaluates a golf recreational exercise program for enhancing survivorship in underrepresented prostate cancer survivors. Golf is a multimodal recreational activity that requires participants to utilize all muscle groups to perform the golf swing, walk over hilly and uneven terrain, maintain balance during putting and squat-like tasks. Physical activity and exercise are beneficial to physical function, cognitive function, psychosocial health, and overall quality of life during prostate cancer survivorship. These aspects of health are impacted by prostate cancer treatment, especially androgen deprivation therapy. Additionally, supervised, group-based activity programs facilitate participation in physical activity. Researchers want to examine the changes in functional abilities, psychosocial health, and quality of life following participation in in a golf program designed for prostate cancer survivors.
Eligibility Criteria
Inclusion Criteria: * First time, primary diagnosis of prostate cancer (PCa) * Currently receiving androgen deprivation therapy (ADT) and/or androgen receptor blocker) for more than 6 months * Older adult male: 55-85 years old * The ability to stand independently without external support * No or minimal golf experience (played \< 5 times in the past 10 years) * English speaking Exclusion Criteria: * Second cancer diagnosis (excluding non-invasive skin cancers) or bone metastases * Prostatectomy less than 6 months prior to study enrollment (prostatectomy is not a requirement for study entry) * Symptomatic cardiovascular disease, active angina, uncontrolled hypertension (systolic blood pressure (SBP) \> 160 or diastolic blood pressure (DBP) \> 90, high resting pulse heart rate (HR) \> 90), symptomatic orthostatic hypotension * Unstable asthma, exacerbated chronic obstructive pulmonary disease (COPD\] * History of injury or orthopedic operation within the last 6 months * Movement disorders (e.g., Parkinson's disease (PD) or other neurological disorders), hemiparesis or paraparesis * Severe vision or hearing problems
Contact & Investigator
George Salem, PhD
PRINCIPAL INVESTIGATOR
University of Southern California
Frequently Asked Questions
Who can join the NCT06500169 clinical trial?
This trial is open to male participants only, aged 55 Years or older, up to 85 Years, studying Localized Prostate Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06500169 currently recruiting?
Yes, NCT06500169 is actively recruiting participants. Contact the research team at Guanrong@usc.edu for enrollment information.
Where is the NCT06500169 trial being conducted?
This trial is being conducted at Los Angeles, United States, Los Angeles, United States.
Who is sponsoring the NCT06500169 clinical trial?
NCT06500169 is sponsored by University of Southern California. The principal investigator is George Salem, PhD at University of Southern California. The trial plans to enroll 20 participants.